SARS-CoV-2
Showing NaN - NaN of 8
SARS-CoV-2, Influenza Trial in Canada, United States (mRNA-1083, Placebo, Influenza Vaccine)
Not yet recruiting
- SARS-CoV-2
- Influenza
- mRNA-1083
- +3 more
-
Anniston, Alabama
- +172 more
Oct 18, 2023
Asymptomatic SARS-CoV-2 Detection in Children
Completed
- Covid19
- SARS-CoV-2
-
Birmingham, Alabama
- +4 more
Nov 1, 2022
SARS-CoV-2 Trial in Canada, United States (mRNA-1273, Placebo)
Recruiting
- SARS-CoV-2
- mRNA-1273
- +2 more
-
Birmingham, Alabama
- +89 more
Oct 7, 2022
COVID-19, SARS-CoV-2 Trial in Worldwide (AZD1222, AZD2816)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- AZD1222
- AZD2816
-
Brasilia, Brazil
- +34 more
Jun 27, 2022
SARS-CoV-2 Trial in United Kingdom (mRNA-1273.529, mRNA-1273, mRNA-1273.214)
Recruiting
- SARS-CoV-2
- mRNA-1273.529
- +2 more
-
Aberdeen, Aberdeenshire, United Kingdom
- +28 more
Apr 11, 2022
SARS-CoV-2-specific Immunity in Individuals Who Have Recovered
Active, not recruiting
- SARS-CoV-2
- COVID-19
- Sample collection
-
Birmingham, Alabama
- +52 more
Sep 3, 2021
Coronavirus Infection, Covid-19, SARS-CoV-2 Trial in Birmingham (Ensifentrine Dose 1, Placebo pMDI)
Unknown status
- Coronavirus Infection
- +2 more
- Ensifentrine Dose 1
- Placebo pMDI
-
Birmingham, AlabamaThe University of Alabama at Birmingham
Apr 19, 2021
